MECHANISMS OF RESISTANCE TO IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH NEPHROTIC SYNDROME

The present article provides a modern look at the main mechanisms of resistance to immunosuppressive therapy in patients with nephrotic syndrome. The urgency of the problem is because, in most cases, the molecular basis of steroid-resistant nephrotic syndrome is not known, which has now led to the study of the pharmacokinetic, dynamic and genetic aspects of immunosuppressive drugs used to treat nephrotic syndrome, as well as the possibility of genotyping before treatment. The article deals with mechanisms and causes of resistance to the main immunosuppressive drugs used to treat nephrotic syndrome, which fully reflects the need for further study of pharamcogenomics and pharmacokinetics of this disease. We also consider the possibility of genotyping before treatment, which in the long term will allow us to take into account the patient's genotypic characteristics for the purpose of prescribing optimal regimens for immunosuppressive therapy and for carrying out a personalized therapy for nephrotic syndrome.

1. Julia M.B., Christine E.S., Raman V. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics 2013; 23(10): 563–585. DOI: 10.1097/FPC.0b013e328364db84.

2. Ruochen C., Aihua Z. Mechanisms of Glucocorticoid Resistance in Idiopathic Nephrotic Syndrome. Kidney Blood Press Res 2013; 37: 360–378. DOI: 10.1159/000350163.

3. Encio I.J., Detera-Wadleigh S.D. The genomic structure of the human glucocorticoid receptor. J Biol Chem 1991; 266: 7182– 7188. PMID: 1707881.

4. Tang Y., Getzenberg R.H., Vietmeier B.N., Stallcup M.R., Eggert M., Renkawitz R., DeFranco D.B. The DNA-binding and tau2 transactivation domains of the rat glucocorticoid receptor constitute a nuclear matrix-targeting signal. Mol Endocrinol 1998; 12: 1420–1431. DOI: 10.1210/mend.12.9.0169.

5. Zhou J., Cidlowski J. The human glucocorticoid receptor: One gene, multiple proteins and diverse responses. Steroids 2005; 70: 407–417. DOI: 10.1016/j.steroids.2005.02.006.

6. Duma D., Jewell C.M., Cidlowski J.A. Multiple glucocorticoid receptor isoforms and mechanisms of posttranslational modification. J Steroid Biochem Mol Biol 2006; 102: 11–21. DOI: 10.1016/j.jsbmb.2006.09.009.

7. Patari-Sampo A., Ihalmo P., Holthofer H. Molecular basis of the glomerular filtration: nephrin and the emerging protein complex at the podocyte slit diaphragm. Ann Med 2006; 38: 483–492. DOI: 10.1080/07853890600978149.

8. Schoeb D.S., Chernin G., Heeringa S.F., Matejas V., Held S., Vega-Warner V., Bockenhauer D., Vlangos C.N. et al. Nineteen novel NPHS1 mutations in a worldwide cohort of patients with congenital nephrotic syndrome (CNS). Nephrol Dial Transplant 2010; 25: 2970–2976. DOI: 10.1093/ndt/gfq088.

9. Kitamura A., Tsukaguchi H., Hiramoto R., Shono A., Doi T., Kagami S., Iijima K. A familial childhood-onset relapsing nephrotic syndrome. Kidney Int 2007; 71: 946–951. DOI: 10.1038/ sj.ki.5002110.

10. Heeringa S.F., Vlangos C.N., Chernin G., Hinkes B., Gbadege-sin R., Liu J., Hoskins B.E., Ozaltin F., Hildebrandt F. Thirteen novel NPHS1 mutations in a large cohort of children with congenital nephrotic syndrome. Nephrol Dial Transplant 2008; 23: 3527–3533. DOI: 10.1093/ndt/gfn271.

11. Horinouchi I., Nakazato H., Kawano T. and et al. In situ evaluation of podocin in normal and glomerular diseases. Kidney Int 2003; 64: 2092–2099. DOI: 10.1046/j.1523-1755.2003.00303.x

12. Kapturczak M.H., Meier-Kriesche H.U., Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc 2004; 36: 25S– 32S. DOI: 10.1007/s40265-017-0746-9.

13. Grimm M., Rinaldi M., Yonan N.A., Arpesella G., Arizon Del Pra-do J.M., Pulpon L.A. et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients — a large European trial. Am J Transplant 2006; 6: 1387–1397. DOI: 10.1111/j.1600-6143.2006.01300.x.

14. Dai Y., Hebert M.F., Isoherranen N., Davis C.L., Marsh C., Shen D.D. et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34:836– 847. DOI: 10.1124/dmd.105.008680.

15. Kolars J.C., Awni W.M., Merion R.M., Watkins P.B. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488– 1490. PMID: 1683920.

16. Alak A.M., Moy S. Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients. Transplant Proc 1997; 29: 2487–2490. PMID: 9270821.

17. Copeland K.R., Yatscoff R.W., McKenna R.M. Immunosuppressive activity of cyclosporine metabolites compared and characterized by mass spectroscopy and nuclear magnetic resonance. Clin Chem 1990; 36: 225–229. PMID: 2137384.

18. Hubbard P.A., Shen A.L., Paschke R., Kasper C.B., Kim J.J. NADPH cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer. J Biol Chem 2001. DOI: 10.1074/ jbc.M101731200.

19. Tang H.L., Xie H.G., Yao Y., Hu Y.F. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonex-pressers than expressers. Pharmacogenet Genomics 2011; 21: 713–720. DOI: 10.1097/FPC.0b013e32834a48ca.

20. Santoro A., Felipe C.R., Tedesco-Silva H., Medina-Pestana J.O., Struchiner C.J., Ojopi E.B. et al. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics 2011; 12: 1293–1303. DOI: 10.2217/pgs.11.70.

21. Amirimani B., Ning B., Deitz A.C., Weber B.L., Kadlubar F.F., Rebbeck T.R. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 2003; 42: 299–305. DOI: 10.1002/em.10199.

22. Thorp M., DeMattos A., Bennett W., Barry J., Norman D. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. Transplantation 2000; 69: 1218–1220. PMID: 10762229.

23. Anglicheau D., Verstuyft C., Laurent-Puig P. et al. Association of the multidrug resistance-1 gene singlenucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14: 1889–1896. PMID: 12819250.

24. Zheng H., Zeevi A., Schuetz E., Lamba J., McCurry K., Griffith B.P. et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol 2004; 44:.135–140. DOI: 10.1177/0091270003262108.

25. Grinyo J., Vanrenterghem Y., Nashan B., Vincenti F., Ekberg H., Lindpaintner K. et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int 2008; 21: 879–891. DOI: 10.1111/j.1432-2277.2008.00679.x.

26. Lamba V., Sangkuhl K., Sanghavi K. Mycophenolic acid Pathway, Pharmacokinetics/Pharmacodynamics. www.pharmgkb. org/pathway/ PA165964832? Previous Query ¼ mycophenolate. Accessed 24 February 2016. DOI: 10.2217/pgs.15.181.

27. Kim S.H., Jeong I.H., Hyun J.W., Joung A., Jo H.J., Hwang S.H. et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol 2015; 72 (9): 989–995. DOI: 10.1001/jamaneurol.2015.1276.